Our Top 5 Most Undervalued U.S. Stocks,
Using Our DDDD: (Deep Dive Due Diligence)
5 U.S. Stocks With
Massive Upside Potential
Updated March 15th, 2026
Let's begin by saying that any investment is risky.
Before investing in anything, do your own due diligence.
Do not consider anything we, nor anyone else, writes as
financial advice. Only you can click the "Buy" button.
Also, please note this is not a "paid advertisement",
it is a free service we offer to our portfolio clients,
and share with our followers in the investing public on Social Media as well:
#1 LRHC La Rosa Holdings Corp.
EASILY the Largest Upside on Wall Street right now.
Read our deep dive report on the merger announced
last week...click here.
Curr=$.75 PT =$16.73 a 2,300% upside post merger,
including any needed dilution.
​​
#2 ELAB PMGC Holdings Inc.
This tiny float (1.08M) stock company
PMGC Holdings Inc. recently filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing identifies George Kovalyov, director of the company, purchased $19,600 in options...
They recently announced the completion of the acquisition of a $3+ per year manufacturing company, SVM Machining,
a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets.
A PR was huge for an ELAB subsidiary:
"NorthStrive Biosciences Signs License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health."​
Headquartered in beautiful and affluent Newport Beach, CA,
this conglomerate is operating with a brilliant business plan.
Where would seem like "fracturing: to the old way of thinking,'
in today's economy what PMGC is doing is "bootstraping" with income producing subsidiaries, and income producing investments:
They own 1,639,521 shares of CITR, purchased for around a $2.75 average per share, now worth around $7.33/share.
Earning about $8 million from just that.
They have a list of parts, too, subsidiaries, mega cash, and their core company:
​
Subsidiary / Cash Valuation Table
--------------------------------------
Component Value w/ Per-Share Value
(Based on the 1.19M OS & 1.08K float:)
​
Cash (unrestricted) $15.5 M = $13.02/sh
AGA Precision Systems LLC =$0.20/sh
Pacific Sun Packaging Inc =$0.45/sh
CMC Aerospace =$0.25/sh
North Strive Bio Sciences = $.50/sh
PMGC Research Inc. =$0.15/sh
PMGC Capital LLC =$0.20/sh
CITR Ownership =$10.07/sh
SMV Manufacturing $3/sh
​
This above is not including the undisclosed stake in the nuclear company MMR. Anything "nuclear" nowadays has clear stock rocket potential, even just holdings.
-Aerospace contracts are rumored imminent now with the newly acquired ISO AS9100.
For small caps, this Certification achievement is RARE,
this PR was extremely under recognized as HUGE,
as LUCRATIVE Aerospace contracts can come at any moment.
Think of the recent "skyrocketing" successes of RKLB, ASTS, SIDU, LUNR, and others. SpaceX will be the largest IPO in history, said to be $30B or more...With a valuation of $1T to $1.5T.​
​​Curr $5.34 Our PT=$33.65 (Short term, but the actual value of cash, and subsidiaries at just face value is easily closer to Finviz's $45.64 BV. (630% realistic upside potential.)
​#3 SHPH Shuttle Pharmaceuticals
SHPH has our attention with not only the bargain price of
under $1/sh, but ongoing events as well:-SHPH shot up like a space shuttle 400% in a previous Friday's pre-market trading...due to the 50% gioblastoma trial enrollment PR. The results from Phase 1 were astounding.-Also this recent PR: "Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer".-High "Insider Ownership" is always a very good sign, SHPH boasts 46.58% plus 5+% institutionally owned. SHPH also presented in Las Vegas in April.
A Reverse Split and offering were completed recently, so they're compliant and fully funded now.
The recently acquired Molecule A.I. platform can be a game
changer in the fight against cancer, in which Shuttle has an even
greater chance now, of curing.
Curr=$.94 PT =$4 (425% realistic upside potential.)
​
#4 IXHL Incannex Healthcare Inc.
The sequential, and almost concurrent PRs of "Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X" and "Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilize ATM in Near Term​"
and backing by this Benzinga article
"Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial"
PRs came just 48 days after another important PR: "Incannex Healthcare Cancels All Outstanding Series A Warrants". With a respectable 21.94% insider ownership, now solid balance sheet, gangbuster trial results, and clearly a dedicated following, this stock is now clearly QUITE undervalued. A "short squeeze" is in the cards, as Dark Pool greed will most likely backfire on the Bears.
Curr=$3.23 =$12.11 (375% realistic upside potential.)​
​
#5 MGRX Mangoceuticals, Inc.
It was the clear cut WINNER (UP 48%) on news, and winner by volume (343.66 million shares traded) on Friday.
The company reported momentum for its $99-per-month injectable testosterone replacement therapy (TRT) program.
Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update.
Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.
Curr=$.3637 PT=$1.22 (335% realistic upside potential.)​​​